David Gascoigne, CEO of Almaden Genomics [Photo: Almaden]
Almaden—which was formerly part of IBM Research before launching as a standalone company in 2022 under Catalyze Dallas ownership—aims to complement its g.nome workflow platform with the new service business. The goal: providing solutions that streamline data analysis and management in drug discovery, diagnostics, biotech research, and more.